Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

Our platform, designed with regulatory compliance in mind, enhances clinical research by using algorithms to sift through unstructured EMR data to identify life-threatening conditions. We create cutting-edge technologies that broaden access to groundbreaking healthcare solutions through Clinical Trials. Our dedicated team is committed to saving lives by facilitating access to therapeutic innovations that are still being researched. We strongly advocate that every patient should be informed and empowered regarding their potential to engage in clinical trials that could offer significant therapeutic benefits. As a forward-thinking healthcare AI research firm, we have created a computational platform that identifies patients who meet a detailed set of criteria for participation in clinical trials, ensuring that the most suitable candidates are considered for these critical studies. Through our work, we aim to revolutionize the way patients connect with life-changing treatment opportunities.

Description

Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

MySQL
SQL

Integrations

MySQL
SQL

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Dyania Health

Founded

2019

Country

United States

Website

dyaniahealth.com

Vendor Details

Company Name

Hillo

Country

France

Website

www.hillo.ai/

Product Features

Natural Language Processing

Co-Reference Resolution
In-Database Text Analytics
Named Entity Recognition
Natural Language Generation (NLG)
Open Source Integrations
Parsing
Part-of-Speech Tagging
Sentence Segmentation
Stemming/Lemmatization
Tokenization

Product Features

Alternatives

Alternatives

Altis Labs Nota Reviews

Altis Labs Nota

Altis Labs
Ember Reviews

Ember

MetiStream
Altis Labs Nota Reviews

Altis Labs Nota

Altis Labs